Guoyuan Securities gives Marubi an overweight rating. Comments on the 2021 annual report and 2022 first quarter report: sales expenses increase, profit side is under pressure, and the Douyin channel is growing rapidly – yqqlm

Key Data Concepts:   

? These are the company names, stock quotes, topics, and entities related to this data.

000728 300713 Guangdong Marubi Biotechnology Guoyuan Securities Company Limited Shenzhenrease Technology Science, Technology Annual, Special Corporate Meeting Annual Report Research, Development Financial, Business Service Paper, Packaging Product Currency Market, Exchange Securities Espionage, Intelligence Technology, Engineering Series Cosmetics Economy, Business, Finance

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Home » News » Guoyuan Securities gives Marubi an overweight rating. Comments on the 2021 annual report and 2022 first quarter report: sales expenses increase, profit side is under pressure, and the Douyin channel is growing rapidly – yqqlm